Valeant, now Bausch Health, paid $1 billon in 2015 for Sprout Pharmaceuticals’ female libido drug Addyi, only to sell it back in 2017. Now as the drug is still nowhere near the blockbuster status ...
HSDD affects 40%-55% of postmenopausal women, often due to hormonal changes, impacting sexual desire and quality of life.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback